title: The effect of dietary bacillus natto productive protein on in vivo endogenous thrombolysis.
abstract: The influence of dietary bacillus natto productive protein (BNPP) on endogenous thrombolysis was investigated in the rat. Animals were given a standard feed for 14 weeks, to which 0.2 or 1% BNPP was added. Thrombolysis was evaluated using an He-Ne laser-induced thrombosis model in mesenteric microvessels. Changes in thrombus volume, reflecting thrombolysis, decreased to 82% of the initial value in the control group. In contrast, the thrombus volume decreased to 67% in the animals fed 0.2% BNPP, and decreased to 51% in the group given 1% BNPP. The extent of thrombolysis in the 1% BNPP group was equivalent to that seen in animals treated with a bolus intravenous infusion of 0.2 mg/kg tissue plasminogen activator. The results demonstrated that the dietary administration of BNPP enhanced endogenous thrombolysis in a dose-dependent manner. Argatroban (2 mg/kg/h) enhanced endogenous fibrinolysis only in control animals, but not in the BNPP groups. The results support the suggestion that dietary supplementation with BNPP may provide a simple means to promote fibrinolysis not only in the treatment of thromboembolism but also in the prevention of venous occlusion.
authors.affiliation: Laboratory of Physiology, Faculty of Nutrition, Kobe Gakuin University, Kobe, Japan. tsutomu@nutr.kobegakuin.ac.jp
authors.forename: T
authors.initials: T
authors.lastname: Yamashita
authors.forename: E
authors.initials: E
authors.lastname: Oda
authors.forename: J C
authors.initials: JC
authors.lastname: Giddings
authors.forename: J
authors.initials: J
authors.lastname: Yamamoto
mesh_terms: D000818:Animals; D001120:Arginine / Q000031:analogs & derivatives; D001407:Bacillus; D001426:Bacterial Proteins / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D019587:Dietary Supplements; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D005342:Fibrinolysis / Q000187:drug effects; D008297:Male; D008833:Microcirculation; D010875:Pipecolic Acids / Q000008:administration & dosage / Q000494:pharmacology; D051381:Rats; D017208:Rats, Wistar; D013152:Splanchnic Circulation; D013449:Sulfonamides; D013810:Therapeutic Equivalency; D015912:Thrombolytic Therapy; D013927:Thrombosis / Q000188:drug therapy / Q000517:prevention & control*
chemical_list: C498116:Bacillus natto productive protein, Bacillus; D001426:Bacterial Proteins; D010875:Pipecolic Acids; D013449:Sulfonamides; D001120:Arginine; C031942:argatroban